Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu, 30013, Taiwan.
Department of Neurosurgery, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, 33305, Taiwan; Centre for Tissue Engineering, Chang Gung Memorial Hospital, Taoyuan, 33305, Taiwan; College of Medicine, Chang Gung University, Taoyuan, 33302, Taiwan; Centre for Biomedical Science and Engineering, National Tsing Hua University, Hsinchu, 30013, Taiwan.
Biomaterials. 2021 May;272:120765. doi: 10.1016/j.biomaterials.2021.120765. Epub 2021 Mar 24.
Ischemic stroke, and the consequent brain cell death, is a common cause of death and disability worldwide. Current treatments that primarily aim to relieve symptoms are relatively inefficient in achieving brain tissue regeneration and functional recovery, and thus novel therapeutic options are urgently needed. Although cell-based therapies have shown promise for treating the infarcted brain, a recurring challenge is the inadequate retention and engraftment of transplanted cells at the target tissue, thereby limiting the ultimate therapeutic efficacy. Here, we show that transplantation of preassembled three-dimensional (3D) spheroids of mesenchymal stem cells (MSCs) and vascular endothelial cells (ECs) results in significantly improved cell retention and survival compared with conventional mixed-cell suspensions. The transplanted 3D spheroids exhibit notable neuroprotective, proneurogenic, proangiogenic and anti-scarring potential as evidenced by clear extracellular matrix structure formation and paracrine factor expression and secretion; this ultimately results in increased structural and motor function recovery in the brain of an ischemic stroke mouse model. Therefore, transplantation of MSCs and ECs using the 3D cell spheroid configuration not only reduces cell loss during cell harvesting/administration but also enhances the resultant therapeutic benefit, thus providing important proof-of-concept for future clinical translation.
缺血性脑卒中是一种常见的全球致死致残病因。目前主要针对缓解症状的治疗方法在实现脑组织再生和功能恢复方面相对低效,因此迫切需要新的治疗选择。尽管基于细胞的疗法已显示出治疗梗死大脑的潜力,但一个反复出现的挑战是移植细胞在靶组织中的保留和植入不足,从而限制了最终的治疗效果。在这里,我们发现与传统的混合细胞悬液相比,间充质干细胞(MSCs)和血管内皮细胞(ECs)预先组装的三维(3D)球体的移植可显著提高细胞保留和存活率。移植的 3D 球体表现出明显的神经保护、神经生成、血管生成和抗瘢痕形成潜力,这表现在细胞外基质结构形成和旁分泌因子表达和分泌方面;这最终导致缺血性脑卒中小鼠模型的结构和运动功能恢复增加。因此,使用 3D 细胞球体结构移植 MSC 和 EC 不仅减少了细胞收获/给药过程中的细胞损失,而且增强了治疗效果,从而为未来的临床转化提供了重要的概念验证。